Analyst recommends Novartis as a Buy for long-term investors, BioAge a Hold, following strategic partnership for age-related ...

Leerink Partners analyst Joseph Schwartz has maintained their neutral stance on PTCT stock, giving a Hold rating yesterday.Stay Ahead of the ...

Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing the right to receive one share of its common ...

WARREN, N.J., Jan. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 3, 2025, the company approved 1,200 restricted stock units ("RSUs"), each representing ...

Christine Marie Utter, Senior Vice President and Chief Accounting Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), recently sold shares of the company's common stock totaling $132,492. The ...

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...

Eric Pauwels, the Chief Executive Officer of PTC Therapeutics, Inc. (NASDAQ:PTCT), recently sold shares of the company's common stock valued at approximately $167,550. The transactions occurred ...

2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug Application (NDA) for the treatment of children and adults living with ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...